A Randomized Phase III Trial of Complete Mesocolic Excision Compared with Conventional Surgery for Right Colon Cancer: Interim Analysis of a Nationwide Multicenter Study of the Italian Society of Surgical Oncology Colorectal Cancer Network (CoME-in trial).
Maurizio DegiuliAridai H Resendiz AguilarMario SolejDanila AzzolinaGiulia MarchioriFrancesco CorcioneUmberto BracaleRoberto PeltriniMaria M Di NuzzoGianandrea BaldazziDiletta CassiniGiuseppe S SicaBrunella PirozziAndrea MuratoreMarcello CalabròElio JovineRaffaele LombardiGabriele AnaniaMatteo ChiozzaWanda PetzPaolo PizziniRoberto PersianiAlberto BiondiRossella ReddavidPublished in: Annals of surgical oncology (2023)
Interim data show that CME for right colon cancer in referral centers is safe and feasible and does not increase perioperative complications. The study documented with evidence that quality of surgery and LN yield are higher after CME, and this is essential for continuation of patient recruitment and implementation of an optimal comparison. Trial registration The trial was registered at ClinicalTrials.gov with the code NCT04871399 and with the acronym CoME-In trial.
Keyphrases
- phase iii
- clinical trial
- phase ii
- open label
- study protocol
- minimally invasive
- primary care
- placebo controlled
- coronary artery bypass
- palliative care
- randomized controlled trial
- quality improvement
- cardiac surgery
- acute coronary syndrome
- case report
- coronary artery disease
- risk factors
- percutaneous coronary intervention
- acute kidney injury